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Edited by Michael R. BubbAbstract Mitochondria have emerged recently as eﬀective tar-
gets for novel anti-cancer drugs referred to as ‘mitocans’. We
propose that the molecular mechanism of induction of apoptosis
by mitocans, as exempliﬁed by the drug a-tocopheryl succinate,
involves generation of reactive oxygen species (ROS). ROS then
mediate the formation of disuﬁde bridges between cytosolic Bax
monomers, resulting in the formation of mitochondrial outer
membrane channels. ROS also cause oxidation of cardiolipin,
triggering the release of cytochrome c and its translocation via
the activated Bax channels. This model may provide a general
mechanism for the action of inducers of apoptosis and anticancer
drugs, mitocans, targeting mitochondria via ROS production.
 2006 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Cytochrome cMitochondria are organelles essential for life and death [1].
While they are a major source of energy in the form of ATP,
mitochondria are also involved in a number of intricate and
regulated processes that culminate in apoptotic cell death.
The precise steps whereby mitochondria provide both signals
and downstream mediators provoking the transition of cells
to the commitment phase of the apoptogenic process are not
well understood. Notwithstanding, an increasing number of
anti-cancer drugs are being discovered that induce cell death
by targeting mitochondria. These agents, referred to as ‘mito-
cans’ [2], destabilise mitochondria, causing cytosolic release of
apoptogenic factors [3]. Several recent reviews have high-Abbreviations: BH3 domain, Bcl-2 homology-3 domain; CL, cardio-
lipin; Cyt c, cytochrome c; MIM, mitochondrial inner membrane;
MitoQ, mitochondrially targeted coenzyme Q; (Mn)SOD, (manga-
nese) superoxide dismutase; MOM, mitochondrial outer membrane;
ROS, reactive oxygen species; TM domain, trans-membrane domain;
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doi:10.1016/j.febslet.2006.05.072lighted the role of mitocans as novel anti-cancer drugs that tar-
get mitochondria [4–6].
One group of mitocans includes redox-silent analogues of
vitamin E, epitomised by a-tocopheryl succinate (a-TOS) [7].
This agent has been shown to selectively kill malignant cells
at concentrations non-toxic to normal cells and tissues [8]
and regardless of whether the cells contain mutations in key
tumour suppressor genes, such as p53 [9]. Importantly,
a-TOS also suppresses several diﬀerent types of experimental
tumours, including the diﬃcult-to-treat melanomas, mesothe-
liomas and HER-2-positive breast carcinomas [10–13]. The
molecular mechanism underlying the selectivity of agents like
a-TOS for malignant cells results from at least two mecha-
nisms. One relates to the ester structure of a-TOS and is due
to the generally higher levels of esterases in normal cells such
as hepatocytes, colonocytes, ﬁbroblasts or cardiomyocytes that
cleaves a-TOS to produce vitamin E [5,14]. Another reason for
the cancer cell-speciﬁc toxicity of a-TOS may be related to the
inherent property of many inducers of apoptosis to trigger pro-
grammed cell death by initially inducing cells to accumulate
reactive oxygen species (ROS) which in turn cause a cascade
of subsequent reactions leading to transition of the cell into
the commitment phase [15]. a-TOS has been reported to induce
ROS accumulation in many diﬀerent cancer cell lines, most
probably resulting in the generation of superoxide anion radi-
cals [13,16–18]. In addition, it has been reported that cancer
cells have less antioxidant defences than normal cells: for
example, malignant cells have lower levels of expression of
manganese superoxide dismutase (MnSOD) compared to their
non-malignant equivalents [19]. Moreover, we have found that
proliferating endothelial cells are susceptible to a-TOS-induced
apoptosis unlike their conﬂuent (growth-arrested) counter-
parts [20] expressing higher levels of MnSOD (J.N., unpub-
lished results).
It has been clearly documented that apoptosis induced by a-
TOS is accompanied by Bax recruitment to mitochondria and
cytochrome c (Cyt c) release into the cytosol [4]. An important
role for Bax in apoptosis is also supported by other data.
Hence, Bax has been shown to relocate to mitochondria upon
exposure of cells to a-TOS [21,22]; apoptosis induced by a-
TOS is enhanced by over-expression of Bax [21]; and pre-treat-
ment of cells with Bax antisense oligodeoxynucleotides [22] or
siRNA [16] inhibits apoptosis mediated by a-TOS. Thus, inblished by Elsevier B.V. All rights reserved.
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translocation of Bax to mitochondria, channel formation and
cytosolic mobilisation of Cyt c. These events are all suppressed
by the presence of antioxidants, like MnSOD or the mitoc-
hondrially targeted coenzyme Q (MitoQ) (J.N., unpublished
data). In addition, upregulation of the anti-apoptotic Bcl-2
family proteins protects cancer cells from a-TOS-induced
apoptosis [22]. The ratio of the levels of expression of pro-
apoptotic Bax versus anti-apoptotic Bcl-2/Bcl-xL proteins is
important for modulating the outcome of an apoptogenic
trigger [23,24]. Hence, an important question is by what
mechanism do agents like a-TOS promote Bax and Cyt c
translocation, key events at the onset of apoptosis induced
via the intrinsic pathway?
We have recently found that one molecular target of a-TOS
is complex II (succinate-ubiquinone oxidoreductase) of the
mitochondrial redox chain, in particular the ubiquinone
(UbQ)-binding site (S.J.R. and J.N., submitted for publica-
tion). Interestingly, other agents that target oxidative phos-
phorylation, such as mitochondrial uncouplers, have been
shown to induce apoptosis, generally resulting in collapse of
the mitochondrial inner trans-membrane potential followed
by Bax and Cyt c mobilisation [25–29], not dissimilar to the
process observed for a-TOS. Recently, an anticancer agent
tamoxifen has been shown to impair the function of complex
I resulting in formation of ROS [30]. Moreover, mutations in
complex II that reduce the ﬂow of electrons to UbQ result in
increased production of superoxide anion radicals and have
been suggested to contribute to tumorigenesis [31,32]. Thus,
we propose that blocking electron transfer along the mitochon-
drial redox chain by a-TOS displacing UbQ leads to electrons
recombining with molecular oxygen to yield superoxide anion
radicals. Since SOD and MitoQ inhibit the apoptosis-promot-
ing accumulation of superoxide anion radicals in cells exposed
to a-TOS, generation of ROS is central to the early apoptotic
signalling preceding cell death.
Numerous reports have proposed a role for ROS in apop-
tosis. ROS most likely play two major roles in mitochondrial
translocation of Bax and cytosolic mobilisation of Cyt c. In a
healthy cell, monomeric Bax is located predominantly in the
cytoplasm, with the C-terminal mitochondrial docking motif
hidden due to its conformation. Upon initiation of apoptosis,
Bax conformation changes exposing the docking motif and
provoking dimerisation of Bax, which then moves to the
mitochondrial outer membrane (MOM) where Bax dimers
aggregate to form pores [33]. Several domains within the
Bax molecule are critical for Bax oligomerisation and move-
ment to the MOM, where Bax forms a trans-membrane chan-
nel. These include the Bcl-2 homology-3 (BH3) domain close
to the N-terminus essential for dimerisation of Bax [34,35],
and the C-terminal trans-membrane (TM) or mitochondrial
docking domain important for mitochondrial recognition of
Bax homodimers [36]. It also appears that the Bax BH3 and
TM domains interact with each other during apoptosis signal-
ling [37]. Both dimerisation and exposure of the TM domain
occur before translocation of Bax to mitochondria [38], con-
sistent with these events occurring early during apoptogenic
signalling. Studies have reported that Bax dimers proceed to
form in the cytoplasm and move to the MOM where they
associate into tetramers and octamers thereby allowing larger
molecules, such as Cyt c, to pass through, and that these
‘megachannels’ do not include the voltage-dependent anionicchannel [39,40]. It has been shown that Bax dimerisation and
mitochondrial translocation proceeds prior to mitochondrial
events [26,41] and that the chaperone HSC70, that maintains
proteins in an unfolded state, prevents Bax mitochondrial
translocation to the cytosolic face of the MOM, [42]. Re-
cently, evidence was presented that ROS production causes
dimerisation of Bax in the cytosol by generating disulﬁde
bridges between critical cysteine residues [43]. This occurs in
the presence of ROS, a product of the initial mitochondrial
events in intrinsic apoptogenic signalling, both in whole cells
and in mitochondria-free cytosolic fractions. Computer simu-
lations showed that these disulﬁde bridges change the confor-
mation of Bax, so that it translocates to the MOM [43]. Bax
contains two Cys residues that are exposed and, therefore,
accessible to oxidants [44]. Molecular modelling revealed that
the most favourable disulﬁde bridges in Bax dimers would be
formed by linking Cys162–Cys162 or Cys162–Cys62, with the
latter more likely, since Cys62 is within the BH3 domain of
Bax, which is essential for Bax dimerisation and conforma-
tional change, as well as for the interaction of Bax with the
Bcl-2 and Bcl-xL proteins [45,46]. However, further experi-
mental validation of this proposal is still required. Notwith-
standing, this is the ﬁrst and very important ﬁnding
revealing the molecular mechanism of Bax dimerisation and
translocation in a system where apoptosis is induced by oxi-
dative stress.
Another central player in mitochondrial-dependent apopto-
sis, leading to caspase activation, is Cyt c [47]. This mitochon-
drial inter-membrane protein is anchored to the mitochondrial
inner membrane (MIM) by its aﬃnity for the mitochondria-
speciﬁc phospholipid cardiolipin (CL), and the binding is dis-
rupted upon oxidation of CL by ROS derived from the oxida-
tive phosphorylation complexes [48,49]. Oxidation of CL and
subsequent release of Cyt c are both prevented by endogenous
SOD [48] or exogenous cell-permeable antioxidants [50]. Fur-
thermore, Cyt c alone appears to have an oxidase activity that
results in modiﬁcation of CL and release of the Cyt c protein
from CL [51]. Using oxidative lipidomics, Kagan et al. [51] also
showed that CL was the only phospholipid in mitochondria
oxidised in the early stages of apoptosis initiated by stauro-
sporine or actinomycin D, and that this was triggered by mito-
chondria-dependent generation of ROS. Finally, Vila et al.
[52], have presented evidence that cells deﬁcient in complex I
generate ROS, leading to CL oxidation and subsequent Cyt
c detachment from this phospholipid, followed by cytoplasmic
relocalisation of Cyt c via Bax channels [45]. Collectively, these
results link mitochondrial ROS production, ROS-dependent
Bax dimerisation and formation of channels in the MOM
and release of Cyt c from its binding to the intra-membrane
face of the MIM into the cytoplasm (see Fig. 1).
Mitochondrial proteins Bcl-2 and Bcl-xL exert their anti-
apoptotic activity by diverting Bax and preventing it from
forming MOM channels. These anti-apoptotic Bcl-2 family
members contain BH3 binding domains in the form of a
hydrophobic groove exposed on the cytosolic face of the
MOM, and they both bind Bax via the Bax BH3 domain
[52,53]. Since hetero-dimers between Bax and Bcl-2/Bcl-xL
are favoured over hetero-tetramers [54], it is possible that
Bcl-2 and Bcl-xL capture Bax monomers before they become
‘activated’, i.e. dimerised, thereby preventing Bax from form-
ing channels in MOM [55]. Another recent publication re-
ported a novel function of a-TOS in that it also associates
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Fig. 1. Model for the molecular mechanism of apoptosis initiation by a-tocopheryl succinate. According to this model, there are two roles for a-TOS:
the major role, in which it inhibits oxidative respiration at the level of complex II, and an auxiliary role, which involves its binding to Bcl-2 and Bcl-xL
to allow Bax to form mitochondrial membrane channels. Thus, upon inhibiting the activity of complex II, a-TOS impairs transfer of electrons along
the redox chain. This leads to generation of ROS, such as the superoxide anion radicals. ROS then contribute to the ensuing events as follows. The
cysteine residues on Bax monomers are oxidised to form disulﬁde bridges, whereby the protein dimerises. This changes the conformation of Bax, so
that the mitochondria-docking motif is exposed and the dimers merge in the mitochondrial outer membrane (MOM), forming a channel. ROS also
oxidise cardiolipin (CL) within the mitochondrial inner membrane (MIM). This leads to dissociation of cytochrome c (Cyt c) from the inter-
membrane face of CL. Free Cyt c then escapes via the Bax channel in the MOM into the cytoplasm. a-TOS, occupying the BH3 domains of Bcl-2 and
Bcl-xL, prevents Bax from forming inactive oligomers with Bcl-2 and Bcl-xL, thereby increases the pool of available Bax dimers that form MOM
channels promoting induction of apoptosis.
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Furthermore, a-TOS binding to Bcl-2 or Bcl-xL prevented cap-
ture of the Bax-homologue Bak by the two anti-apoptotic pro-
teins. As a result, there is an increase in the pool of Bak freely
available and required to form or aid in forming channels in
the MOM. Thus, at low levels of a-TOS, binding of the drug
to the MOM-associated Bcl-2 or Bcl-xL may prevent transloca-
tion of a-TOS into mitochondria, where it would otherwise
disrupt the electron ﬂow along the redox chain. In this manner,
Bcl-2/Bcl-xL would be working as an anti-apoptotic mecha-
nism. However, as the levels of drug increase to the point that
they exceed the binding capacity of Bcl-2/Bcl-xL, then the ef-
fects of the drug on the respiratory chain would come into
play, leading to increased ROS production. Since Bax alsobinds to the BH3 domains of Bcl-2/Bcl-xL, it is likely that a-
TOS will, in an analogous manner, allow for the free Bax pool
to also be increased. As a result, Bax dimerisation will be
favoured, promoting formation of MOM channels. Moreover,
excessive levels of a-TOS above the capacity of Bcl-2/Bcl-xL
would facilitate the ROS-dependent dimerisation of Bax, since
monomeric Bax would otherwise be captured via the hydro-
phobic pocket on the cytosolic side of unoccupied Bcl-2 or
Bcl-xL (cf. [54,55]).
The various facets of the model’s components at this stage
make prioritizing each particular one for their relative signiﬁ-
cance to be diﬃcult. As described above, each component
plays an integral part in contributing to the overall induction
and activation of mitochondrial mediated apoptosis. We
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novel class of anti-cancer drugs. However, all of the postulated
mechanisms described may or may not be physiologically rel-
evant in any given situation, and will undoubtedly depend
on considerations such as the cellular O2 conditions, levels of
expression of Bcl-2 family proteins, state of respiration and
other factors that inﬂuence the ﬁnal outcome. Nevertheless,
the fact that SOD or MitoQ addition suppress the extent of
a-TOS induced apoptosis tends to indicate an important role
for the respiratory chain eﬀects as a key triggering event.
In summary, we propose a novel model for the initial events
in apoptosis induced by a-TOS, a compound epitomising the
‘mitocan’ group of anti-cancer agents. Accordingly, a-TOS
inhibits oxidative phosphorylation at the level of complex
II, resulting in generation of superoxide anion radicals. In
the cytosol, ROS catalyse the formation of disulﬁde bridges
between monomers of Bax, causing a conformational change
and dimerisation that is followed by Bax mobilisation to the
MOM to form (mega)channels. In the mitochondria, ROS
triggers the oxidase activity of Cyt c that leads to oxidative
modiﬁcation of CL with ensuing release of Cyt c from its
binding to the MIM phospholipid, followed by Cyt c extru-
sion via the Bax channel to the cytosol. a-TOS also associates
with the cytosolic BH3 binding domains on Bcl-2 and Bcl-xL
in the MOM to prevent the anti-apoptotic proteins trapping
Bax, increasing the Bax available to form MOM channels.
Whilst the model presented was developed using the vitamin
E analogue a-TOS, it can be expected to be valid with minor
modiﬁcations for other mitocans, i.e. anti-cancer agents that
act by targeting mitochondria and causing ROS generation
to promote cancer cell death [2].References
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